
    
      Phase IV, interventional, randomised, double blind, placebo-controlled and parallel study to
      evaluate the clinical efficacy and safety of vitamin D supplementation in hospitalized
      patients with COVID-19.

      Patients will participate in the study for a maximum of 9 weeks, which includes an up to
      6-week treatment period and a maximum of 3-week follow-up period.

      A total of 100 (50 in each group) patients will be randomized in the study and will either
      receive the test treatment or the placebo treatment.
    
  